Table 2.
Immune response and protection of CD1 mice
Dose (μg) | Animal | Non-adjuvanted |
Adjuvanted with 0.05% aluminium hydroxide |
||||
---|---|---|---|---|---|---|---|
ELISA titre (week 4) | NT (week 5) | Virus titre (day 3 p.i.) | ELISA titre (week 4) | NT (week 5) | Virus titre (day 3 p.i.) | ||
0.2 | 1 | 1:102,400 | 1:1522 | ≤1.7 | 1:25,600 | 1:1522 | ≤1.7 |
2 | 1:25,600 | 1:3620 | ≤1.7 | 1:25,600 | 1:1256 | ≤1.6 | |
3 | 1:25,600 | 1:1396 | ≤1.6 | 1:102,400 | 1:1974 | ≤1.5 | |
4 | 1:25,600 | 1:830 | ≤1.6 | 1:25,600 | 1:1810 | ≤1.7 | |
0.04 | 1 | 1:25,600 | 1:905 | ≤1.7 | 1:25,600 | 1:415 | ≤1.6 |
2 | 1:25,600 | 1:190 | ≤1.6 | 1:400 | ≤1:28 | ≤1.6 | |
3 | 1:6400 | 1:587 | ≤1.6 | 1:6400 | 1:349 | ≤1.6 | |
4 | 1:6400 | 1:95 | ≤1.7 | <1:100 | ≤1:33 | 2.2 | |
0.008 | 1 | 1:1600 | 1:113 | ≤1.5 | 1:1600 | 1:37 | ≤1.6 |
2 | 1:6400 | 1:320 | ≤1.7 | 1:1600 | ≤1:37 | ≤1.6 | |
3 | 1:25,600 | 1:415 | ≤1.6 | 1:25,600 | 1:587 | ≤1.6 | |
4 | 1:400 | 1:34 | 2.3 | 1:25,600 | 1:453 | ≤1.6 | |
0.0016 | 1 | 1:400 | ≤1:57 | 3.4 | 1:1600 | 1:160 | ≤1.5 |
2 | 1:1600 | ≤1:57 | ≤1.5 | 1:400 | ≤1:28 | ≤1.5 | |
3 | <1:100 | ≤1:57 | ≤1.6 | 1:1600 | ≤1:28 | ≤1.5 | |
4 | 1:1600 | ≤1:57 | 2.7 | 1:400 | ≤1:28 | 2.3 | |
0.0003 | 1 | 1:100 | ≤1:71 | ≤1.6 | 1:100 | ≤1:57 | 4.8 |
2 | <1:100 | ≤1:57 | 1.9 | <1:100 | ≤1:57 | 3.6 | |
3 | <1:100 | ≤1:71 | 5.6 | 1:100 | ≤1:57 | 3.4 | |
4 | 1:100 | ≤1:57 | 6.0 | 1:400 | ≤1:57 | ≤1.5 | |
None | 1 | <1:100 (pool) | ≤1:57 | 4.5 | |||
2 | ≤1:57 | 4.8 | |||||
3 | ≤1:28 | 5.1 | |||||
4 | ≤1:57 | 3.4 |
p.i.: post inoculation. S-specific antibody titres were measured by ELISA, neutralising antibody titres (NT) by a micro neutralisation assay and SARS-CoV titres of homogenised lung/trachea tissue were determined by a TCID50 assay and are given as log(TCID50/g lung tissue).